GSK plc (LON:GSK) Insider Jonathan Symonds Acquires 1,500 Shares of Stock

GSK plc (LON:GSK) insider Jonathan Symonds bought 1,500 shares of the company’s stock in a transaction on Friday, December 20th. The shares were acquired at an average price of GBX 1,315 ($16.48) per share, with a total value of £19,725 ($24,727.34).

Jonathan Symonds also recently made the following trade(s):

• On Wednesday, October 30th, Jonathan Symonds purchased 7,150 shares of GSK stock. The stock was acquired at an average price of GBX 1,394 ($17.48) per share, for a total transaction of £99,671 ($124,947.98).

GSK Stock Up 1.9 %

GSK stock opened at GBX 1,334 ($16.72) on Tuesday. The firm has a market capitalization of £54.43 billion, a PE ratio of 1,180.53, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. The business’s fifty day simple moving average is GBX 1,387.25. GSK plc has a 52-week low of GBX 1,282.50 ($16.08) and a 52-week high of GBX 1,823.50 ($22.86). The company has a quick ratio of 0.73, a current ratio of 0.82 and a debt-to-equity ratio of 123.04.

GSK Announces Dividend

The firm also recently declared a dividend, which will be paid on Thursday, January 9th. Shareholders of record on Thursday, November 14th will be issued a GBX 15 ($0.19) dividend. This represents a yield of 1.03%. The ex-dividend date of this dividend is Thursday, November 14th. GSK’s dividend payout ratio (DPR) is 5,309.73%.

Wall Street Analysts Forecast Growth

GSK has been the topic of a number of recent research reports. JPMorgan Chase & Co. reaffirmed an “underweight” rating on shares of GSK in a research note on Wednesday, December 11th. Berenberg Bank reduced their price objective on GSK from GBX 1,820 ($22.82) to GBX 1,600 ($20.06) and set a “buy” rating on the stock in a research report on Friday, November 29th. Shore Capital reaffirmed a “buy” rating on shares of GSK in a research note on Wednesday, August 28th. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a GBX 1,850 ($23.19) target price on shares of GSK in a research note on Tuesday, September 3rd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of GBX 1,805.83 ($22.64).

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.